Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge

The RV144 human immunodeficiency virus type 1 (HIV-1) vaccine trial showed a strong association between anti-gp70 V1V2 scaffold (V1V2) and anti-V2 hot spot peptide (V2 HS) antibody responses and reduced risk of HIV infection. Accordingly, a primary goal for HIV vaccines is to enhance the magnitude a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Styles, Tiffany M., Gangadhara, Sailaja, Reddy, Pradeep B. J., Hicks, Sakeenah, LaBranche, Celia C., Montefiori, David C., Derdeyn, Cynthia A., Kozlowski, Pamela A., Velu, Vijayakumar, Amara, Rama Rao
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6798111/
https://ncbi.nlm.nih.gov/pubmed/31341049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00934-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados